Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

natalizumab

- PMLiVE

Novartis announces positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the disease

- PMLiVE

Merck KGaA’s MS drug put on partial clinical hold by FDA

Laboratory results suggested there were two cases of drug-induced liver injury during the phase 3 studies

- PMLiVE

UK launches ‘revolutionary’ trial for progressive MS patients

Octopus is assessing whether existing drugs can be used to help slow disease progression

- PMLiVE

Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

It is estimated that there are over 130,000 people living with the condition in the UK alone

- PMLiVE

Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis

More than ten million adults in the US alone over the age of 50 are estimated to have the condition

- PMLiVE

Sandoz’s high concentration Hyrimoz formulation recommended for use in EU

The recommendation includes multiple indications such as rheumatoid arthritis and Crohn’s disease

- PMLiVE

New UK study finds most MS patients not offered fatigue treatments

Of 4,367 patients surveyed, 30.8% reported having been offered at least one treatment for fatigue

- PMLiVE

World-first trial launches in UK to assess stem cell transplants as first-line MS treatment

The £2.3m StarMS study will compare AHSCT with four other drug treatments

- PMLiVE

Immunic reports promising new data for MS treatment

The treatment helped to lower the rate of confirmed disability worsening over time

- PMLiVE

Sandoz to invest €50m in Austrian manufacturing facility to meet global antibiotic demand

Amoxicillin and other vital penicillin products will benefit from the investment

- PMLiVE

Tiziana completes enrolment of first patient cohort in MS expanded access programme

Foralumab has already demonstrated positive results in patients with non-active SPMS

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links